Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
75.27
+0.51 (0.68%)
At close: May 1, 2026, 4:00 PM EDT
75.30
+0.03 (0.04%)
After-hours: May 1, 2026, 7:45 PM EDT
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,402 employees as of December 31, 2025. The number of employees increased by 333 or 31.15% compared to the previous year.
Employees
1,402
Change (1Y)
333
Growth (1Y)
31.15%
Revenue / Employee
$754,772
Profits / Employee
-$233,222
Market Cap
12.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,402 | 333 | 31.15% |
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
IONS News
- 2 days ago - Ionis to present at upcoming investor conferences - Business Wire
- 4 days ago - Ionis Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - Ionis reports first quarter 2026 financial results and highlights progress on key programs - Business Wire
- 5 days ago - Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B - Business Wire
- 12 days ago - Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting - Business Wire
- 18 days ago - Ionis to hold first quarter 2026 financial results webcast - Business Wire
- 4 weeks ago - FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - GlobeNewsWire
- 5 weeks ago - Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga